Assessing Corvus Pharmaceuticals (CRVS) Valuation After Recent Share Price Momentum

Simply Wall St.02-01

AdvertisementWhy Corvus Pharmaceuticals Stock Is on Investors’ Radar Corvus Pharmaceuticals (CRVS) has drawn attention after large price swings recently, with the share price up sharply over the past ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2608002951?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-02-01 13:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608002951","market":"sg","top_or_hot":-1,"title":"Assessing Corvus Pharmaceuticals (CRVS) Valuation After Recent Share Price Momentum","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementWhy Corvus Pharmaceuticals Stock Is on Investors’ Radar Corvus Pharmaceuticals (CRVS) has drawn attention after large price swings recently, with the share price up sharply over the past ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crvs/corvus-pharmaceuticals/news/assessing-corvus-pharmaceuticals-crvs-valuation-after-recent\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Corvus Pharmaceuticals (CRVS) Valuation After Recent Share Price Momentum</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Corvus Pharmaceuticals (CRVS) Valuation After Recent Share Price Momentum\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-01 13:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crvs/corvus-pharmaceuticals/news/assessing-corvus-pharmaceuticals-crvs-valuation-after-recent><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementWhy Corvus Pharmaceuticals Stock Is on Investors’ Radar Corvus Pharmaceuticals (CRVS) has drawn attention after large price swings recently, with the share price up sharply over the past ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crvs/corvus-pharmaceuticals/news/assessing-corvus-pharmaceuticals-crvs-valuation-after-recent\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CRVS","symbol_name":"Corvus Pharmaceuticals, Inc.","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crvs/corvus-pharmaceuticals/news/assessing-corvus-pharmaceuticals-crvs-valuation-after-recent","article_id":"2608002951","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crvs/corvus-pharmaceuticals/news/assessing-corvus-pharmaceuticals-crvs-valuation-after-recent","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2608002951","pubTimestamp":1769923293,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Why Corvus Pharmaceuticals Stock Is on Investors’ Radar\nCorvus Pharmaceuticals (CRVS) has drawn attention after large price swings recently, with the share price up sharply over the past month and past 3 months, prompting closer scrutiny of its clinical stage pipeline.\nSee our latest analysis for Corvus Pharmaceuticals.\nThe recent 30 day share price return of 182.79% and 90 day return of 169.53% sit alongside a very large 3 year total shareholder return, which points to strong momentum...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"CRVS":"Corvus Pharmaceuticals, Inc.","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","BK4568":"美国抗疫概念","BK4139":"生物科技"},"translate_title":"在近期股价势头后评估Corvus Pharmaceuticals(CRVS)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRVS":1.5,"DCF":1},"content_text":"AdvertisementWhy Corvus Pharmaceuticals Stock Is on Investors’ Radar Corvus Pharmaceuticals (CRVS) has drawn attention after large price swings recently, with the share price up sharply over the past month and past 3 months, prompting closer scrutiny of its clinical stage pipeline. See our latest analysis for Corvus Pharmaceuticals. The recent 30 day share price return of 182.79% and 90 day return of 169.53% sit alongside a very large 3 year total shareholder return, which points to strong momentum despite a 17.53% share price pullback over the past week and a 1.15% decline in the latest session at a last close of $20.70. If Corvus has caught your eye, it can be helpful to see how it compares with other US drug developers, starting with healthcare stocks that are catching attention right now. With no current revenue, ongoing net losses of US$15.08 million and a clinical stage pipeline, Corvus looks like a pure sentiment and prospects story. The key question is whether the recent surge is an opening or if the market is already pricing in future growth. Preferred Multiple of 24.2x Price-to-Book Ratio, Is it justified? Corvus Pharmaceuticals is carrying a P/B of 24.2x at a last close of $20.70, which screens as expensive against both peers and the broader US Biotechs industry. The P/B ratio compares the company’s market value to its book value, so a higher figure usually means investors are paying a premium over the accounting value of net assets. For a clinical stage biotech with no current revenue and ongoing losses, a high P/B often reflects expectations around the pipeline and potential future cash generation rather than current fundamentals. Here, the contrast is stark. The peer average P/B is 4.3x and the wider US Biotechs industry average is 2.6x. This places Corvus far above both benchmarks. That indicates the market is assigning a much richer valuation multiple than is typical for the sector, with sentiment and expectations about future prospects doing most of the work at current levels. See what the numbers say about this price — find out in our valuation breakdown. Result: Price-to-Book of 24.2x (OVERVALUED) However, the story can change quickly if clinical trials disappoint or if ongoing net losses of US$15.08 million a year make future funding more difficult or more dilutive. Find out about the key risks to this Corvus Pharmaceuticals narrative. Another View: Our DCF Estimate Paints a Different Picture While the 24.2x P/B suggests Corvus is expensive versus peers, our DCF model points the other way, with an estimated future cash flow value of $53.69 per share versus the current $20.70. That implies a large gap, so which signal do you trust more: sentiment or cash flows? Look into how the SWS DCF model arrives at its fair value. CRVS Discounted Cash Flow as at Feb 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Corvus Pharmaceuticals for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 875 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.  Build Your Own Corvus Pharmaceuticals Narrative If you see the numbers differently or prefer to rely on your own work, you can quickly build a custom view of Corvus by using Do it your way. A great starting point for your Corvus Pharmaceuticals research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision. Looking for more investment ideas? If Corvus has you thinking about what else might be worth your time, now is the moment to widen your watchlist before other investors get there first.  Spot early movers by checking out these 3528 penny stocks with strong financials that pair smaller share prices with solid financial underpinnings. Explore the AI trend with these 24 AI penny stocks that sit at the intersection of cutting edge tech and market attention. Identify potential value opportunities using these 875 undervalued stocks based on cash flows that highlight companies where cash flow estimates and prices currently appear out of sync.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2608002951","isCrawlerRequest":true}